[{"id":"b0492680-31b9-44ce-b7e1-7f8515ae4865","acronym":"KEYNOTE-E80","url":"https://clinicaltrials.gov/study/NCT05957081","created_at":"2023-07-24T15:08:36.934Z","updated_at":"2025-02-25T16:18:59.236Z","phase":"Phase 1","brief_title":"Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309","source_id_and_acronym":"NCT05957081 - KEYNOTE-E80","lead_sponsor":"PharmAbcine","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PMC-309"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 11/28/2023","start_date":" 11/28/2023","primary_txt":" Primary completion: 09/10/2025","primary_completion_date":" 09/10/2025","study_txt":" Completion: 10/04/2028","study_completion_date":" 10/04/2028","last_update_posted":"2023-11-20"}]